MTL-CEPBA is a small activating RNA targeting for upregulation of C/EBPα. MTL-CEPBA has anti-inflammatory and anti-cancer activity^[1].

MTL-CEBPA does not significantly change total human CD45⁺ cells, and T lymphocytes (hCD4⁺ and hCD8⁺ T cell subsets) in PB. However, MTL-CEBPA treatment increases CD16⁺ granulocytes and CD14⁺ monocytes in peripheral blood (PB)^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

MTL-CEBPA (iv; 3 mg/kg; on days 1, 3, and 5) demonstrates the specific activation of its target C/EBPα mRNA and its downstream gene p21 in naive hu-NSG mice^[1].
MTL-CEBPA restores LPS-induced (12.5 μg; ip; single dose) reduction of C/EBPα and downregulates several genes associated with immune and inflammatory response in an LPS-stimulated humanized NSG model^[1].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Jiehua Zhou, et al. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice. Mol Ther. 2019 May 8;27(5):999-1016.